
    
      A prospective, multi-centre, non-randomized clinical trial with follow-up investigations at
      1, 6 and 12 months. Approximately 250 subjects will be enrolled at 15 Chinese study sites. To
      confirm the safety and efficacy of the Passeo-18 Lux DCB for the interventional treatment of
      new and non-stented re-stenotic lesions in the superficial femoral artery (SFA) and proximal
      popliteal artery (PPA) in a Chinese patient population.
    
  